Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Lifecore Biomedical, Inc. \De\ (LFCR) Non-Current Deffered Revenue (2023 - 2024)

Lifecore Biomedical, Inc. \De\ (LFCR) has 3 years of Non-Current Deffered Revenue data on record, last reported at $4.7 million in Q2 2024.

For Q2 2024, Non-Current Deffered Revenue rose 59.97% year-over-year to $4.7 million; the TTM value through May 2024 reached $4.7 million, up 59.97%, while the annual FY2024 figure was $4.7 million, 59.97% up from the prior year.
Non-Current Deffered Revenue reached $4.7 million in Q2 2024 per LFCR's latest filing, up from $321000.0 in the prior quarter.
Across five years, Non-Current Deffered Revenue topped out at $4.7 million in Q2 2024 and bottomed at $321000.0 in Q4 2023.